Literature DB >> 26546369

Knockdown of hippocampal cysteinyl leukotriene receptor 1 prevents depressive behavior and neuroinflammation induced by chronic mild stress in mice.

Xu-Ben Yu1, Rong-Rong Dong1, Hui Wang2, Jing-Ran Lin1, Yun-Qi An1, Yong Du1, Su-Su Tang1, Mei Hu1, Yan Long1, Hong-Bin Sun1, Ling-Yi Kong1, Hao Hong3.   

Abstract

RATIONALE: Numerous studies have demonstrated that neuroinflammation is associated with depression-like symptoms and neuropsychological disturbances, and cysteinyl leukotriene receptor 1 (CysLT1R) was reported to be involved in neuroinflammation. The pathophysiological role of CysLT1R has been reported in several types of brain damage. However, the role of CysLT1R in depression remains to be elucidated.
OBJECTIVES: We aimed to investigate the effect of hippocampal CysLT1R downregulation on depressive behaviors and neuroinflammatory responses in mice exposed to chronic mild stress (CMS).
RESULTS: We firstly found that expression of hippocampal CysLT1R was gradually increased over CMS exposure, while 3 weeks treatment with fluoxetine reversed the increment of hippocampal CysLT1R expression. Hippocampal CysLT1R knockdown suppressed CMS-induced depressive-like behaviors as evidenced by decreases in immobility time in tail suspension test (TST), decreased latency to feed in novelty-suppressed feeding (NSF) test, and by increase in the number of entries and decrease in time spent in the open arm in elevated plus maze (EPM) test. Increments of hippocampal NF-κB p65, IL-1β, and TNF-α induced by CMS were also prevented by hippocampal CysLT1R knockdown beforehand.
CONCLUSIONS: Hippocampal CysLT1R participates in depression, and knockdown of hippocampal CysLT1R prevents CMS-induced depressive-like behaviors and neuroinflammation, suggesting that suppression of CysLT1R could prevent the development of depression.

Entities:  

Keywords:  Chronic mild stress; Cysteinyl leukotriene receptor 1; Depression; Neuroinflammation

Mesh:

Substances:

Year:  2015        PMID: 26546369     DOI: 10.1007/s00213-015-4136-2

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  52 in total

1.  NF-kappaB is activated and promotes cell death in focal cerebral ischemia.

Authors:  A Schneider; A Martin-Villalba; F Weih; J Vogel; T Wirth; M Schwaninger
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

2.  Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice.

Authors:  Cecile Ducottet; Guy Griebel; Catherine Belzung
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2003-06       Impact factor: 5.067

3.  A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells.

Authors:  Frank Stegmeier; Guang Hu; Richard J Rickles; Gregory J Hannon; Stephen J Elledge
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-01       Impact factor: 11.205

4.  Leptin: a potential novel antidepressant.

Authors:  Xin-Yun Lu; Chung Sub Kim; Alan Frazer; Wei Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-19       Impact factor: 11.205

5.  Icariin exerts an antidepressant effect in an unpredictable chronic mild stress model of depression in rats and is associated with the regulation of hippocampal neuroinflammation.

Authors:  B Liu; C Xu; X Wu; F Liu; Y Du; J Sun; J Tao; J Dong
Journal:  Neuroscience       Date:  2015-03-17       Impact factor: 3.590

Review 6.  Cysteinyl leukotrienes and their receptors: molecular and functional characteristics.

Authors:  R K Singh; S Gupta; S Dastidar; A Ray
Journal:  Pharmacology       Date:  2010-06-02       Impact factor: 2.547

7.  RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells.

Authors:  Jenn-Yah Yu; Stacy L DeRuiter; David L Turner
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-23       Impact factor: 11.205

8.  Leukotriene D4 stimulates the migration but not proliferation of endothelial cells mediated by the cysteinyl leukotriene cyslt(1) receptor via the extracellular signal-regulated kinase pathway.

Authors:  Yu-Mei Yuan; San-Hua Fang; Xiao-Dong Qian; Li-Ying Liu; Li-Hua Xu; Wen-Zhen Shi; Li-Hui Zhang; Yun-Bi Lu; Wei-Ping Zhang; Er-Qing Wei
Journal:  J Pharmacol Sci       Date:  2009-02       Impact factor: 3.337

9.  The effect of the leukotriene receptor antagonist zafirlukast on neurokinin A-induced bronchoconstriction in patients with asthma--A comparison with leukotriene D4 induced broncoconstriction.

Authors:  V Schelfhout; V Van De Velde; R Pauwels; G Joos
Journal:  Pulm Pharmacol Ther       Date:  2007-05-24       Impact factor: 3.410

10.  Antidepressant-like effects of cordycepin in a mice model of chronic unpredictable mild stress.

Authors:  Zhang Tianzhu; Yang Shihai; Du Juan
Journal:  Evid Based Complement Alternat Med       Date:  2014-12-23       Impact factor: 2.629

View more
  11 in total

1.  Effects of Jiaotaiwan on depressive-like behavior in mice after lipopolysaccharide administration.

Authors:  Qian Zhe; Wang Sulei; Tao Weiwei; Long Hongyan; Wang Jianwei
Journal:  Metab Brain Dis       Date:  2016-10-30       Impact factor: 3.584

2.  Hippocampal CysLT1R knockdown or blockade represses LPS-induced depressive behaviors and neuroinflammatory response in mice.

Authors:  Jing-Ran Lin; Shun-Chang Fang; Su-Su Tang; Mei Hu; Yan Long; Arijit Ghosh; Hong-Bin Sun; Ling-Yi Kong; Hao Hong
Journal:  Acta Pharmacol Sin       Date:  2017-01-23       Impact factor: 6.150

3.  Montelukast suppresses the development of irritable bowel syndrome phenotype possibly through modulating NF-κB signaling in an experimental model.

Authors:  Pariya Khodabakhsh; Nilgoon Khoie; Ahmad-Reza Dehpour; Alireza Abdollahi; Mahmoud Ghazi-Khansari; Hamed Shafaroodi
Journal:  Inflammopharmacology       Date:  2022-01-10       Impact factor: 4.473

4.  Chronic social defeat stress increases the amounts of 12-lipoxygenase lipid metabolites in the nucleus accumbens of stress-resilient mice.

Authors:  Satoshi Akiyama; Hirotaka Nagai; Shota Oike; Io Horikawa; Masakazu Shinohara; Yabin Lu; Takashi Futamura; Ryota Shinohara; Shiho Kitaoka; Tomoyuki Furuyashiki
Journal:  Sci Rep       Date:  2022-07-05       Impact factor: 4.996

5.  Atorvastatin ameliorates depressive behaviors and neuroinflammatory in streptozotocin-induced diabetic mice.

Authors:  Zhang Hai-Na; Yu Xu-Ben; Tang Cong-Rong; Cao Yan-Cheng; Yang Fan; Xu Lei-Mei; Sun Ruo-Lan; Wang Ye-Xuan; Liang Jing
Journal:  Psychopharmacology (Berl)       Date:  2019-11-30       Impact factor: 4.530

6.  Immune influences on the brain: new findings and implications for treatment.

Authors:  Theodora Duka; Neil A Harrison; Oliver D Howes
Journal:  Psychopharmacology (Berl)       Date:  2016-05       Impact factor: 4.530

7.  Hippocampal Genetic Knockdown of PPARδ Causes Depression-Like Behaviors and Neurogenesis Suppression.

Authors:  Fang Chen; Xuben Yu; Guoliang Meng; Zhenlin Mei; Yifeng Du; Hongbin Sun; Miranda N Reed; Lingyi Kong; Vishnu Suppiramaniam; Hao Hong; Susu Tang
Journal:  Int J Neuropsychopharmacol       Date:  2019-06-03       Impact factor: 5.176

8.  The role of leukotriene modifying agent treatment in neuropsychiatric events of elderly asthma patients: a nested case control study.

Authors:  Sang Oh Kang; Kyung Hyun Min; Hyun Jeong Kim; Tae Hyeok Kim; Woorim Kim; Kyung Eun Lee
Journal:  Asthma Res Pract       Date:  2021-03-17

9.  Effects of Voluntary Running Wheel Exercise-Induced Extracellular Vesicles on Anxiety.

Authors:  Kyeong Jin Yoon; Suhong Park; Seung Hee Kwak; Hyo Youl Moon
Journal:  Front Mol Neurosci       Date:  2021-07-01       Impact factor: 5.639

10.  Paradoxical Effect of LTB4 on the Regulation of Stress-Induced Corticosterone Production.

Authors:  Gisele A Locachevic; Morgana K B Prado; Karina F Zoccal; Priscilla A T Pereira; Carlos A Sorgi; Mariza Bortolanza; Ana Paula F Peti; Manoela V Fogaça; Francisco S Guimarães; Elaine Del Bel; Lúcia H Faccioli
Journal:  Front Behav Neurosci       Date:  2019-04-16       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.